Myasthenia Gravis: An Acquired Interferonopathy?
Myasthenia gravis (MG) is a rare autoimmune disease mediated by antibodies against components of the neuromuscular junction, particularly the acetylcholine receptor (AChR). The thymus plays a primary role in AChR-MG patients. In early-onset AChR-MG and thymoma-associated MG, an interferon type I (IF...
Main Authors: | Cloé A. Payet, Axel You, Odessa-Maud Fayet, Nadine Dragin, Sonia Berrih-Aknin, Rozen Le Panse |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/7/1218 |
Similar Items
-
Decreased expression of miR-29 family associated with autoimmune myasthenia gravis
by: Mélanie A. Cron, et al.
Published: (2020-10-01) -
The clinical outcome of thymectomy in myasthenia gravis
by: Mirsharifi R, et al.
Published: (2009-02-01) -
Polymorphism of clinical phenotypes and heterogeneity of autoimmune targets of myasthenia gravis
by: Olena Klimova, et al.
Published: (2020-09-01) -
Altered expression of fragile X mental retardation-1 (FMR1) in the thymus in autoimmune myasthenia gravis
by: Scott Thomas, et al.
Published: (2021-11-01) -
The role of thymectomy in myasthenia gravis: A programmatic approach to thymectomy and perioperative management of myasthenia gravis
by: Ahmed AL-Bulushi, et al.
Published: (2021-06-01)